KPV

What Is KPV? The Tripeptide From Alpha-MSH

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

KPV is a tripeptide (lysine, proline, valine) corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone. At 342.43 Da it is among the smallest research peptides in circulation, and it retains reported anti-inflammatory activity without the melanocortin receptor effects that drive pigmentation.

Key facts

Sequence
Lys-Pro-Val
Length
3 residues
Molecular weight
342.43 Da
Formula
C16H30N4O4
PubChem CID
125672 (as Lys-Pro-Val)
Parent
alpha-MSH, residues 11-13
Parent MW
1,664.9 Da
PubMed records
~34 on anti-inflammatory work

Where it comes from

Alpha-melanocyte-stimulating hormone is a 13-residue peptide best known for driving pigmentation through melanocortin receptors. It also has well-described anti-inflammatory activity, and that activity was localised to its C-terminal three residues, Lys-Pro-Val. KPV is those three residues synthesised alone.

Why isolating the tripeptide was the point

Alpha-MSH does two quite different things, and for research on the anti-inflammatory arm the pigmentation activity is a confound rather than a bonus. Separating the C-terminal fragment was an attempt to keep one and discard the other. It is the same reductionist logic that produced the 7-residue thymosin beta-4 fragment some papers call TB-500, applied to a hormone with two distinct effects. KPV is supplied here both on its own and as one of the four KLOW peptides.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

How small it actually is

Three residues and 342.43 Da makes KPV the smallest compound in this library apart from GHK at 340.38. For comparison, ipamorelin is 711.9, BPC-157 is 1,419.5, and retatrutide is around 4,731. That size has real consequences: rapid clearance, minimal structure, and very little for an analytical method to work with.

What the literature reports

Roughly 34 indexed records on KPV's anti-inflammatory work. Kannengiesser and colleagues reported anti-inflammatory potential in murine colitis models in Inflammatory Bowel Disease in 2008. Xiao and colleagues examined orally targeted delivery via hyaluronic acid-functionalised carriers in Molecular Therapy in 2017. That is a delivery paper, which tells you the compound's own oral bioavailability was the obstacle being addressed.

The identifier trap

Searching PubChem for KPV returns 2-oxo-5-phenylpentanoic acid, an unrelated organic compound at 192.21 Da. The peptide is indexed under Lys-Pro-Val at CID 125672. Anyone checking a certificate by searching the three-letter abbreviation will find the wrong molecule, which is worth knowing before doing it.

Regulatory position

KPV holds no marketing authorisation from the MHRA, EMA or FDA. It is supplied here for laboratory research only, and no claim is made about inflammation or any condition in any person.

Frequently asked questions

What does KPV stand for?

The single-letter codes for its three residues: lysine (K), proline (P), valine (V).

Why does PubChem give the wrong compound for KPV?

The three-letter string matches an unrelated organic acid. The peptide is indexed as Lys-Pro-Val, CID 125672.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.